Salcaprozic Acid

Salcaprozic Acid

SCHEMBL29385752

O=C(O)CCCCCCCNC(=O)c1ccccc1O

nearest known ligand 0.81

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 1/20 0.70
ALDH1A1 P00352 2/20 0.66
HTT P42858 2/20 0.66
NPC1 O15118 1/20 0.66
MAPT P10636 1/20 0.66
HPGD P15428 1/20 0.66
TSHR P16473 1/20 0.66
NPSR1 Q6W5P4 1/20 0.66
HSD17B10 Q99714 1/20 0.66
NLRP1 Q9C000 1/20 0.66
ALOX5 P09917 1/20 0.64
MAPK1 P28482 1/20 0.61
NAMPT P43490 1/20 0.59
HDAC7 Q8WUI4 1/20 0.56
NR1H4 Q96RI1 2/20 0.55
KDM4E B2RXH2 1/20 0.55
CYP1A2 P05177 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
HDAC6 Q9UBN7 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL664024 1.00 NAAA (0.70) NAAAALDH1A1HTTNPC1MAPT
SCHEMBL13593340 1.00 NAAA (0.70) NAAAALDH1A1HTTNPC1MAPT
SCHEMBL6383063 1.00 NAAA (0.70) NAAAALDH1A1HTTNPC1MAPT
SCHEMBL2331916 1.00 NAAA (0.70) NAAAALDH1A1HTTNPC1MAPT
Salcaprozic Acid SCHEMBL4586235 1.00 NAAA (0.70) NAAAALDH1A1HTTNPC1MAPT
SCHEMBL14088979 1.00 NAAA (0.70) NAAAALDH1A1HTTNPC1MAPT
SCHEMBL14088978 1.00 NAAA (0.70) NAAAALDH1A1HTTNPC1MAPT
Salcaprozic Acid SCHEMBL845833 0.98 NAAA (0.68) NAAAALDH1A1HTTNPC1MAPT
Salcaprozic Acid SCHEMBL2159928 0.98 NAAA (0.68) NAAAALDH1A1HTTNPC1MAPT
SCHEMBL2331880 0.98 NAAA (0.68) NAAAALDH1A1HTTNPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260069697-A1 METHOD OF TREATING CANCER INTENSITY THERAPEUTICS INC (US) 2026-03-12 US claimed
CN-119950684-A Pharmaceutical composition containing bioactive substances and preparation method and application thereof 北京悦康科创医药科技股份有限公司 2025-05-09 CN claimed
EP-4284774-B1 NOVEL SYNTHESIS OF SALCAPROZIC ACID BY AMIDE FORMATION NOVO NORDISK AS (DK) 2025-03-12 EP claimed
EP-4429704-A1 IONIC LIQUID COMPOSITIONS I2O Therapeutics, Inc. (US) 2024-09-18 EP claimed
CN-118541170-A Ionic liquid composition I2O治疗公司 2024-08-23 CN claimed
EP-4392020-A1 LYOTROPIC LIQUID CRYSTALLINE NANOSYSTEMS WITH ENCAPSULATED BIOACTIVE MACROMOLECULES Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. (GR) 2024-07-03 EP claimed
CN-118063339-A Preparation method of sodium 8- (2-hydroxybenzoylamino) octoate 安徽大学 2024-05-24 CN claimed
CN-117835969-A Lyotropic liquid crystal nanosystems with encapsulated bioactive macromolecules 联康药业克雷恩特塞提斯制药实验室有限责任公司 2024-04-05 CN claimed
CN-117731624-A Solid pharmaceutical composition comprising GLP-1 receptor agonist and application 杭州澳赛诺生物科技有限公司 2024-03-22 CN claimed
CN-117402073-A Preparation method of 8- (2-hydroxybenzoyl) caprylic acid 扬州市普林斯医药科技有限公司 2024-01-16 CN claimed
CN-115651230-B PVC (polyvinyl chloride) coated polyester yarn and preparation method thereof 浙江恒百华化纤有限公司 2023-11-14 CN claimed
US-20230338251-A1 METHOD OF TREATING CANCER INTENSITY THERAPEUTICS, INC. 2023-10-26 US claimed
CN-116745261-A Novel method for synthesizing 8- [ (2-hydroxybenzoyl) amino) octanoic acid (salcap acid) by amide formation 诺和诺德股份有限公司 2023-09-12 CN claimed
CN-116444392-A Polypeptide protein medicine oral absorption promoter and preparation method and application thereof 中国药科大学 2023-07-18 CN claimed
WO-2023086499-A1 IONIC LIQUID COMPOSITIONS I2O THERAPEUTICS, INC. (US) 2023-05-19 WO claimed
CN-112898220-B Preparation method of N- (8- [ 2-hydroxybenzoyl ] -amino) sodium caprylate and intermediate thereof 旺山旺水(连云港)制药有限公司 2023-04-07 CN claimed
WO-2023026067-A1 LYOTROPIC LIQUID CRYSTALLINE NANOSYSTEMS WITH ENCAPSULATED BIOACTIVE MACROMOLECULES UNI-PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. (GR) 2023-03-02 WO claimed
CN-115651230-A PVC (polyvinyl chloride) coated polyester yarn and preparation method thereof 浙江恒百华化纤有限公司 2023-01-31 CN claimed
WO-2022162132-A1 NOVEL SYNTHESIS OF SALCAPROZIC ACID BY AMIDE FORMATION NOVO NORDISK A/S (DK) 2022-08-04 WO claimed
CN-110636837-B Pharmaceutical composition of CYP17 inhibitor and preparation method thereof 江苏恒瑞医药股份有限公司 2022-05-24 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230338251-A1 METHOD OF TREATING CANCER PBK, GZMB, NPC1L1 NAAA 1268/4885ALDH1A1 3990/4885HTT 4127/4885
US-20260069697-A1 METHOD OF TREATING CANCER PBK, GZMB, KLRK1 NAAA 1314/4885ALDH1A1 4469/4885HTT 4565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.